🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  2. Anti-CD20-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  3. Anti-CD30-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  4. Anti-CD38 antibody Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Antiphospholipid Syndrome

    phase 2 small molecule active

    1 trial

  5. Anti-GPRC5D CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  6. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial

  7. Anti-LeY-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myeloid Malignancies

    phase 2 mab active

    1 trial

  8. Anti-PD-1 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. Anti-PD-1 antibody drug named Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IV HCC

    phase 2 small molecule active

    1 trial

  10. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  12. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Apatinib mesylate tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  14. Atezolizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Aumolertinib Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Stage IV

    phase 2 small molecule active

    1 trial

  16. Autologous BCMA-targeting CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  17. Autologous hematopoietic stem cell infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolonged Cytopenia Following CAR-T Therapy

    phase 2 mab active

    1 trial

  18. Avapritinib, azacitidine, Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 2 small molecule active

    1 trial

  19. Avatrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Severe Aplastic Anemia

    phase 2 small molecule active

    2 trials

  20. Avatrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  21. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  22. Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  23. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  24. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources